Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

BACKGROUND: The bevacizumab and irinotecan protocol is considered a standard treatment regimen for recurrent malignant glioma. Recent advances in immunotherapy have hinted that vaccination with dendritic cells could become an alternative salvage therapy for the treatment of recurrent malignant gliom...

Descripción completa

Detalles Bibliográficos
Autores principales: Artene, Stefan-Alexandru, Turcu-Stiolica, Adina, Hartley, Richard, Ciurea, Marius Eugen, Daianu, Oana, Brindusa, Corina, Alexandru, Oana, Tataranu, Ligia Gabriela, Purcaru, Stefana Oana, Dricu, Anica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108618/
https://www.ncbi.nlm.nih.gov/pubmed/27877052
http://dx.doi.org/10.2147/OTT.S112842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108618/
https://www.ncbi.nlm.nih.gov/pubmed/27877052
http://dx.doi.org/10.2147/OTT.S112842

Ejemplares similares